Affordable high performance BiOptix offers a high-sensitivity label-free ESPR technology (404pi) at a price point hundreds of thousands lower than comparable systems, presenting a compelling value proposition for academic labs and small biotech firms seeking premium capability on a tighter budget.

Strategic partnerships Collaboration with Nobel laureate Dr. Jan Hall signals strong credibility in technology development, which can be leveraged to engage potential customers in higher education, government labs, and research institutes seeking validated, cutting-edge instrumentation.

Niche applications The instrument supports a wide range of label-free biomolecular interactions and advanced workflows such as kinetic rate measurement, fragment screening, and epitope mapping, enabling targeted outreach to researchers in protein interactions, drug discovery, and diagnostic research.

Growth through funding Current funding runway (13M) and sub–$1M revenue stage present an opportunity to position BiOptix as a rapid-path ROI vendor for expanding labs and startups scaling their assay capabilities, with value-focused pilots and phased deployments.

Cost of ownership Emphasize lower operating costs and easier software for experimental design and control as a differentiator against larger competitors, appealing to labs prioritizing total cost of ownership and user-friendly workflows.